| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA467559
Max Phase: Preclinical
Molecular Formula: C20H15FN4O4
Molecular Weight: 394.36
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCOC(=O)c1ncn2c1CN=C(c1cccc([N+](=O)[O-])c1)c1cc(F)ccc1-2
Standard InChI: InChI=1S/C20H15FN4O4/c1-2-29-20(26)19-17-10-22-18(12-4-3-5-14(8-12)25(27)28)15-9-13(21)6-7-16(15)24(17)11-23-19/h3-9,11H,2,10H2,1H3
Standard InChI Key: AARNVULOXUAICV-UHFFFAOYSA-N
Associated Targets(Human)
GABA A receptor alpha-1/beta-1/gamma-2 83 Activities
GABA-A receptor; alpha-1/beta-2/gamma-2 1171 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Mus musculus 284745 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 394.36 | Molecular Weight (Monoisotopic): 394.1077 | AlogP: 3.45 | #Rotatable Bonds: 4 |
| Polar Surface Area: 99.62 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 3.96 | CX LogP: 3.73 | CX LogD: 3.73 |
| Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.38 | Np Likeness Score: -1.14 |
References
| 1. Anzini M, Braile C, Valenti S, Cappelli A, Vomero S, Marinelli L, Limongelli V, Novellino E, Betti L, Giannaccini G, Lucacchini A, Ghelardini C, Norcini M, Makovec F, Giorgi G, Ian Fryer R.. (2008) Ethyl 8-fluoro-6-(3-nitrophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate as novel, highly potent, and safe antianxiety agent., 51 (15): [PMID:18637672] [10.1021/jm8002944] |
| 2. Anzini M, Valenti S, Braile C, Cappelli A, Vomero S, Alcaro S, Ortuso F, Marinelli L, Limongelli V, Novellino E, Betti L, Giannaccini G, Lucacchini A, Daniele S, Martini C, Ghelardini C, Di Cesare Mannelli L, Giorgi G, Mascia MP, Biggio G.. (2011) New insight into the central benzodiazepine receptor-ligand interactions: design, synthesis, biological evaluation, and molecular modeling of 3-substituted 6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepines and related compounds., 54 (16): [PMID:21751815] [10.1021/jm2001597] |
Source
Source(1):